Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Cullinan Therapeutics, Inc.’s reported figures.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s EBIT?
- Cullinan Therapeutics, Inc. (CGEM) reported EBIT of -$57.25M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s EBIT changed year-over-year?
- Cullinan Therapeutics, Inc.'s EBIT increased by 24.5% year-over-year, from -$75.8M to -$57.25M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s EBIT?
- Over 3 years (2021 to 2025), Cullinan Therapeutics, Inc.'s EBIT has grown at a 52.6% compound annual growth rate (CAGR), from -$67.95M to -$241.65M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Cullinan Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude